| アブストラクト | INTRODUCTION: Tizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events. OBJECTIVES: Our aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2. METHODS: A disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture. RESULTS: A total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest. More than half of the reports identified tizanidine as having a suspect or interacting role (n = 59, 66.3%), and the reports more frequently involved women (n = 58, 65.1%). The median age was 56.1 years (standard deviation 17.1). Some of the important safety signals included interactions between tizanidine in a suspect or interacting role and ciprofloxacin (ROR for hypotension 28.1, 95% confidence interval [CI] 19.2-41.2) or fluvoxamine (ROR for hypotension 36.9, 95% CI 13.1-103.4), and also when reported in "any role" with ciprofloxacin (ROR for hypotension 6.3, 95% CI 4.7-8.5), fluvoxamine (ROR for hypotension 11.4, 95% CI 4.5-28.8), and zafirlukast (ROR for falls 16.0, 95% CI 6.1-42.1). CONCLUSIONS: Reports involving tizanidine and a CYP1A2 inhibitor have higher odds of reporting hypotension. This study suggests that concurrent use of tizanidine with CYP1A2 inhibitors may lead to serious health consequences associated with low blood pressure such as falls and fractures. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2022/7/15 |
|---|
| 投稿者 | Villa-Zapata, Lorenzo; Gomez-Lumbreras, Ainhoa; Horn, John; Tan, Malinda S; Boyce, Richard D; Malone, Daniel C |
|---|
| 組織名 | Department of Pharmacy Practice, College of Pharmacy, Mercer University, Atlanta,;GA, USA.;Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30 S 2000;E, Salt Lake City, UT, 84112, USA.;Department of Pharmacy, School of Pharmacy, University of Washington, Seattle,;WA, USA.;Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA,;USA.;E, Salt Lake City, UT, 84112, USA. dan.malone@utah.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35834155/ |
|---|
